Drug Database
Back to search

Poland· PL-100087044

Fostimon

A urofollitropin product containing urofollitropinum, registered in Poland by IBSA Farmaceutici Italia S.r.l.. The same ATC class is registered in 11 of our 19 countries.

ATC G03GA04

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedFostimonATCG03GA04REGISTER NO.PL-100087044PACKS LISTED4CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about urofollitropinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Urofollitropin is registered in 11 of 19 countries.

Countries holding a registration under ATC G03GA04 (urofollitropin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search urofollitropin products by name

Urofollitropin · ATC G03GA04

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Urofollitropinum
Manufacturer
IBSA Farmaceutici Italia S.r.l.
Country
Poland (PL)
ATC code
G03GA04
ATC class
Urofollitropin
Defined daily dose
75 E, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 4

1 priced
  • gtin
    05909991107581
  • gtin
    05909991083229
  • gtin
    05909991107598
  • gtin
    05909991083212
    1 fiol. z prosz.po 75 j.m. + 1 amp. z rozp.po 1 ml
    PLN 75.17

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for urofollitropin.

Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check urofollitropin against other medicinesHow interaction checks work

Urofollitropin · interactions on record

1 record

  • 1 moderate

Most severe, free to view

  • GanirelixH01CC01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Urofollitropin in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All urofollitropin products

Authorised across Europe · EMA

The same active substance is authorised in 19 EEA countries. Names it is sold under:

  • Austria · Fostimon, Fostimon Pfs
  • Belgium · Fostimon, Fostimon Kit
  • Bulgaria · Фостимон
  • Cyprus · Fostimon, Fostimon Pfs
  • Czechia · Fostimon
  • Denmark · Fostimon, Fostimon Set
  • Spain · Fostipur, Fostipur Kit
  • Finland · Fostimon, Fostimon Set
  • France · Fostimon, Fostimonkit
  • United Kingdom (Northern Ireland) · Fostimon, Fostimon Pfs
  • Greece · Altermon
  • Hungary · Fostimon Hp
  • Ireland · Fostimon, Fostimon Pfs
  • Italy · Fostimon
  • Luxembourg · Fostimon, Fostimon Kit
  • Netherlands · Fostimon, Fostimon Set
  • Norway · Fostimon, Fostimon Set
  • Sweden · Fostimon, Fostimon Set
  • Slovakia · Fostimon Hp

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9d87c293-76f8-4684-bfbf-a46e5dd42ef7
GET /v1/drugs/9d87c293-76f8-4684-bfbf-a46e5dd42ef7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań",
  "source": "urpl",
  "strength": "75 j.m.",
  "packaging": "05909991107581 ¦ Rp ¦ 5127\n1 fiol. 75 j.m. ¦ 1 amp.-strzyk. 1 ml rozp.\n05909991083212 ¦ Rp ¦ 24945\n1 fiol. 75 j.m. ¦ 1 amp. 1 ml rozp.\n05909991083229 ¦ Rp ¦ 24946\n10 fiol. 75 j.m. ¦ 10 amp. 1 ml rozp.\n05909991107598 ¦ Rp ¦ 58308\n10 fiol. 75 j.m. ¦ 1 amp.-strzyk. 1 ml rozp.",
  "substance": "Urofollitropinum 75 j.m.",
  "common_name": "Urofollitropinum",
  "pl_product_id": "100087044",
  "pozwolenie_nr": "10832",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about urofollitropin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console